LEADS BIOLABS-B (09887): First Patient Successfully Dosed in Phase Ib/II Trial of LBL-024 for Melanoma Treatment

Stock News

Sep 12

LEADS BIOLABS-B (09887) announced that the first patient has been successfully dosed in a Phase Ib/II clinical trial (NCT07099430) evaluating opatasumib (LBL-024), a PD-L1/4-1BB bispecific antibody, as monotherapy or combination therapy for first-line treatment of advanced melanoma.

The Phase Ib/II multicenter clinical trial is led by Professor Chen Yu from Fujian Cancer Hospital, with participation from multiple hospitals nationwide. The study aims to evaluate the efficacy and safety of opatasumib as a single agent or in combination with other agents for treating advanced melanoma.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1188794473"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1188794473\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1188794473?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-12 12:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1188794473","market":"fut","top_or_hot":-1,"title":"LEADS BIOLABS-B (09887): First Patient Successfully Dosed in Phase Ib/II Trial of LBL-024 for Melanoma Treatment","media":"Stock News","content":"<p>LEADS BIOLABS-B (09887) announced that the first patient has been successfully dosed in a Phase Ib/II clinical trial (NCT07099430) evaluating opatasumib (LBL-024), a PD-L1/4-1BB bispecific antibody, as monotherapy or combination therapy for first-line treatment of advanced melanoma.</p>\n<p>The Phase Ib/II multicenter clinical trial is led by Professor Chen Yu from Fujian Cancer Hospital, with participation from multiple hospitals nationwide. The study aims to evaluate the efficacy and safety of opatasumib as a single agent or in combination with other agents for treating advanced melanoma.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>LEADS BIOLABS-B (09887): First Patient Successfully Dosed in Phase Ib/II Trial of LBL-024 for Melanoma Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLEADS BIOLABS-B (09887): First Patient Successfully Dosed in Phase Ib/II Trial of LBL-024 for Melanoma Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-09-12 12:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>LEADS BIOLABS-B (09887) announced that the first patient has been successfully dosed in a Phase Ib/II clinical trial (NCT07099430) evaluating opatasumib (LBL-024), a PD-L1/4-1BB bispecific antibody, as monotherapy or combination therapy for first-line treatment of advanced melanoma.</p>\n<p>The Phase Ib/II multicenter clinical trial is led by Professor Chen Yu from Fujian Cancer Hospital, with participation from multiple hospitals nationwide. The study aims to evaluate the efficacy and safety of opatasumib as a single agent or in combination with other agents for treating advanced melanoma.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1188794473","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1188794473","pubTimestamp":1757651064,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"LEADS BIOLABS-B (09887) announced that the first patient has been successfully dosed in a Phase Ib/II clinical trial (NCT07099430) evaluating opatasumib (LBL-024), a PD-L1/4-1BB bispecific antibody,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","09887":"维立志博-B"},"translate_title":"LEADS BIOLABS-B（09887）：LBL-024治疗黑色素瘤的Ib/II期试验中首位成功给药的患者","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09887":1},"content_text":"LEADS BIOLABS-B (09887) announced that the first patient has been successfully dosed in a Phase Ib/II clinical trial (NCT07099430) evaluating opatasumib (LBL-024), a PD-L1/4-1BB bispecific antibody, as monotherapy or combination therapy for first-line treatment of advanced melanoma.\nThe Phase Ib/II multicenter clinical trial is led by Professor Chen Yu from Fujian Cancer Hospital, with participation from multiple hospitals nationwide. The study aims to evaluate the efficacy and safety of opatasumib as a single agent or in combination with other agents for treating advanced melanoma.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}